BidaskClub cut shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) from a hold rating to a sell rating in a report issued on Tuesday morning.
KERX has been the subject of a number of other research reports. Morgan Stanley reiterated an equal weight rating and set a $7.00 price objective (up previously from $4.00) on shares of Keryx Biopharmaceuticals in a research report on Tuesday, July 25th. Maxim Group upped their price objective on Keryx Biopharmaceuticals from $7.00 to $9.00 and gave the company a buy rating in a research report on Monday, May 15th. Zacks Investment Research cut Keryx Biopharmaceuticals from a buy rating to a hold rating in a research report on Monday, July 17th. ValuEngine cut Keryx Biopharmaceuticals from a hold rating to a sell rating in a research report on Friday, June 2nd. Finally, Cowen and Company reiterated a market perform rating on shares of Keryx Biopharmaceuticals in a research report on Tuesday, July 25th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the stock. Keryx Biopharmaceuticals has a consensus rating of Hold and an average price target of $7.48.
Keryx Biopharmaceuticals (NASDAQ KERX) traded up 1.10% during mid-day trading on Tuesday, hitting $6.42. The stock had a trading volume of 950,163 shares. Keryx Biopharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.38. The company’s 50 day moving average price is $7.24 and its 200 day moving average price is $6.15. The firm’s market cap is $762.38 million.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.60. The firm had revenue of $15.10 million for the quarter, compared to analysts’ expectations of $14.51 million. Keryx Biopharmaceuticals had a negative net margin of 431.89% and a negative return on equity of 2,902.87%. The firm’s revenue was up 62.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.42) EPS. Analysts anticipate that Keryx Biopharmaceuticals will post ($1.23) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Lowered to “Sell” at BidaskClub” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://stocknewstimes.com/2017/08/12/keryx-biopharmaceuticals-inc-nasdaqkerx-lowered-to-sell-at-bidaskclub-2.html.
A number of hedge funds have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. raised its stake in Keryx Biopharmaceuticals by 4.2% in the second quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 590 shares in the last quarter. OZ Management LP bought a new stake in Keryx Biopharmaceuticals during the first quarter valued at about $109,000. Usca Ria LLC bought a new stake in Keryx Biopharmaceuticals during the first quarter valued at about $128,000. Jane Street Group LLC bought a new stake in Keryx Biopharmaceuticals during the first quarter valued at about $141,000. Finally, Legal & General Group Plc raised its stake in Keryx Biopharmaceuticals by 1.2% in the first quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 300 shares in the last quarter. 57.06% of the stock is owned by institutional investors and hedge funds.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.